echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Yangzijiang's 18 injections will lead the list with 3 billion varieties

    Yangzijiang's 18 injections will lead the list with 3 billion varieties

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    226 ,3,201930。,228(+),TOP10,18。
     
     
     :
     
    ,,H+/K+-ATP,、、、-()。
     
    、、、、,。,2019、、()30,,,30%;,20%。
     
    13 domestic companies submitted supplementary applications for the consistency evaluation of lansoprazole for injection or reported production under the new classification.
    Among them, the products of Shandong Luoxin Pharmaceutical and Osaikang have been successfully evaluated, and the products of Yangzijiang are expected to be the third.
     
    After the conformity evaluation of chemical drug injections was officially launched, the number and speed of over-evaluation of injections have been greatly increased.
    According to data from Minai.
    com, 228 injections ( counted by drug name + company name) have passed or deemed to have passed the consistency evaluation.
    Among the TOP10 injection over-evaluated companies, Yangtze River leads with 18 injections.
     
    Top 5 companies with the number of over-rated injections
     
    With the increase in the number of over-reviewed products, injections will become the "protagonist" of the national centralized procurement in the future, and Yangtze River's advantage in centralized procurement will be highlighted.
     
    Yangtze River has reviewed injections
    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Source: Mi Nei.
    com database, announcement of listed companies
     
      Note: The statistics are as of February 24.
    If there are any omissions, please correct me!
      Medical Network News on February 26 A few days ago, Yangzijiang entered the administrative examination and approval stage with the imitation of the 3 types of lansoprazole for injection.
    The sales scale of this product in China's public medical institutions in 2019 exceeded 3 billion yuan.
    According to data from Meinenet, there are currently 228 injections (in terms of drug name + company name) that have passed or deemed to have passed the consistency evaluation.
    Among the TOP10 injection over-evaluated companies, Yangzijiang leads with 18 injections.
     
     
     Source: official website of the State Food and Drug Administration
     
      Lansoprazole is a proton pump inhibitor, a benzimidazole derivative that can specifically and non-competitively act on H+/K+-ATPase, and is clinically used to treat gastric ulcer and duodenal ulcer , Reflux esophagitis, Zoe-Al syndrome (gastrinoma), etc.
     
      At present, the main dosage forms of lansoprazole commonly used in China are tablets, enteric-coated tablets, capsules, enteric-coated capsules, injections, etc.
    Among them, injections are widely used.
    According to data from Meinenet, in 2019, the sales of lansoprazole for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 3 billion yuan.
    From the perspective of the competitive landscape of manufacturers Shandong Luoxin Pharmaceutical has the highest market share, with more than 30%; followed by Osaikang, with a market share of more than 20%.
     
      13 domestic companies submitted supplementary applications for the consistency evaluation of lansoprazole for injection or reported production under the new classification.
    Among them, the products of Shandong Luoxin Pharmaceutical and Osaikang have been successfully evaluated, and the products of Yangzijiang are expected to be the third.
     
      After the conformity evaluation of chemical drug injections was officially launched, the number and speed of over-evaluation of injections have been greatly increased.
    According to data from Minai.
    com, 228 injections ( counted by drug name + company name) have passed or deemed to have passed the consistency evaluation.
    Among the TOP10 injection over-evaluated companies, Yangtze River leads with 18 injections.
     
      Top 5 companies with the number of over-rated injections
     
      With the increase in the number of over-reviewed products, injections will become the "protagonist" of the national centralized procurement in the future, and Yangtze River's advantage in centralized procurement will be highlighted.
     
      Yangtze River has reviewed injections
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Source: Mi Nei.
    com database, announcement of listed companies
     
      Note: The statistics are as of February 24.
    If there are any omissions, please correct me!
      Medical Network News on February 26 A few days ago, Yangzijiang entered the administrative examination and approval stage with the imitation of the 3 types of lansoprazole for injection.
    The sales scale of this product in China's public medical institutions in 2019 exceeded 3 billion yuan.
    According to data from Meinenet, there are currently 228 injections (in terms of drug name + company name) that have passed or deemed to have passed the consistency evaluation.
    Among the TOP10 injection over-evaluated companies, Yangzijiang leads with 18 injections.
     
     
     
     Source: official website of the State Food and Drug Administration
     
      Lansoprazole is a proton pump inhibitor, a benzimidazole derivative that can specifically and non-competitively act on H+/K+-ATPase, and is clinically used to treat gastric ulcer and duodenal ulcer , Reflux esophagitis, Zoe-Al syndrome (gastrinoma), etc.
     
      At present, the main dosage forms of lansoprazole commonly used in China are tablets, enteric-coated tablets, capsules, enteric-coated capsules, injections, etc.
    Among them, injections are widely used.
    According to data from Meinenet, in 2019, the sales of lansoprazole for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 3 billion yuan.
    From the perspective of the competitive landscape of manufacturers Shandong Luoxin Pharmaceutical has the highest market share, with more than 30%; followed by Osaikang, with a market share of more than 20%.
    Hospital hospital hospital
     
      13 domestic companies submitted supplementary applications for the consistency evaluation of lansoprazole for injection or reported production under the new classification.
    Among them, the products of Shandong Luoxin Pharmaceutical and Osaikang have been successfully evaluated, and the products of Yangzijiang are expected to be the third.
     
      After the conformity evaluation of chemical drug injections was officially launched, the number and speed of over-evaluation of injections have been greatly increased.
    According to data from Minai.
    com, 228 injections ( counted by drug name + company name) have passed or deemed to have passed the consistency evaluation.
    Among the TOP10 injection over-evaluated companies, Yangtze River leads with 18 injections.
    Drugs Drugs Drugs enterprise business enterprise
     
      Top 5 companies with the number of over-rated injections
      
     
      With the increase in the number of over-reviewed products, injections will become the "protagonist" of the national centralized procurement in the future, and Yangtze River's advantage in centralized procurement will be highlighted.
     
      Yangtze River has reviewed injections
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Source: Mi Nei.
    com database, announcement of listed companies
      
     
      Note: The statistics are as of February 24.
    If there are any omissions, please correct me!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.